[ad_1]
Islamabad A Chinese pharmaceutical company invited the National Institute of Health (NIH) of Pakistan to collaborate in the clinical trials of its newly developed inactivated coronavirus vaccines (COVID-19) in the country.
This clinical trial will help the Chinese pharmaceutical company know whether or not the vaccine will be successful in treating patients infected with COVID-19 and whether it has any side effects in humans.
According to Pakistani media reports, the clinical trial will begin in the next three months.
Currently, no country in the world has been successful in preparing the deadly coronavirus vaccine. Pakistan is confident that if these clinical trials are successful, it will be able to acquire this vaccine from China as soon as possible.
A vaccine is declared safe for human use only after several stages of clinical trials. Clinical trials of the vaccine are generally performed on animals rather than humans. However, successful tests of a vaccine in animals do not always give the same results in humans.
Human clinical trials have many dangers, as they also involve the possibility of risking life due to side effects or other biological reasons. On April 13, the head of the World Health Organization (WHO), Tedros Adhanom Ghebreyesus, said that the coronavirus COVID-19 is 10 times more deadly than swine flu and that only a vaccine can completely stop the transmission of coronavirus.
Pakistan has around 11 thousand coronavirus patients and the number of deaths is around 230. The chances of rapid spread of COVID-19 infection have increased in Pakistan and it is also assumed that in the next week more than 20 thousand people In Pakistan, you can suffer from COVID-19 infection and around 500 people can end up losing their lives.
[ad_2]
